

Financial news for CBMG dated on 2020-05-06: Cellular Biomedicine Gr Q1 EPS \$(0.600) Down From \$(0.510) YoY

Financial news for CBMG dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for CBMG dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for CBMG dated on 2020-03-05: BTIG Research Downgrades Cellular Biomedicine Gr to Neutral

Financial news for CBMG dated on 2020-02-24: Cellular Biomedicine Says Received New Prelim. Non-Binding Proposal For \$19.50/Share

Financial news for CBMG dated on 2020-01-08: 48 Biggest Movers From Yesterday

Financial news for CBMG dated on 2020-01-07: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CBMG dated on 2019-12-30: Cellular Biomedicine Group Announces Engagement Of Independent Advisors By Special Committee Formed To Evaluate Strategic Alternatives Including \$19.50/Share Preliminary Non-Binding Proposal

Financial news for CBMG dated on 2019-12-07: Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T at ASH 2019

Financial news for CBMG dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for CBMG dated on 2019-11-12: 10 Biggest Price Target Changes For Tuesday

Financial news for CBMG dated on 2019-11-12: Baird Downgrades Cellular Biomedicine Gr to Neutral, Lowers Price Target to \$19

Financial news for CBMG dated on 2019-11-11: Cellular Biomedicine Shares Resume Trade, Up 4-5%

Financial news for CBMG dated on 2019-11-11: Cellular Biomedicine Shares To Resume Trade At 10:30 a.m. EST

Financial news for CBMG dated on 2019-11-11: UPDATE: Cellular Biomedicine Offer From Consortium Led By CEO Tony Liu, Other Senior Mgmt. Members, Hillhouse Bio, TF Capital, Dangdai Int'l., Mission Right

Financial news for CBMG dated on 2019-11-11: Cellular Biomedicine Group Reports Receipt Of Prelim. Non-Binding Go Private Offer At \$19.50/Share In Cash

Financial news for CBMG dated on 2019-11-11: Cellular Biomedicine Group Shares Halted, News Pending

Financial news for CBMG dated on 2019-11-06: Cellular Biomedicine Gr Q3 EPS \$(0.82) Misses \$(0.67) Estimate

Financial news for CBMG dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for CBMG dated on 2019-09-17: Benzinga's Top Upgrades, Downgrades For September 17, 2019

Financial news for CBMG dated on 2019-09-17: BTIG Initiates Coverage On Cellular Biomedicine Gr with Buy Rating, Announces \$19 Price Target

Financial news for CBMG dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for CBMG dated on 2019-08-06: Cellular Biomedicine Gr Q2 EPS \$(0.63) Misses \$(0.52) Estimate

Financial news for CBMG dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for CBMG dated on 2019-06-25: Cantor Fitzgerald Initiates Coverage On Cellular Biomedicine Gr with Overweight Rating, Announces \$27 Price Target

Financial news for CBMG dated on 2019-06-17: Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in

China

Financial news for CBMG dated on 2019-04-30: Cellular Biomedicine Gr Q1 EPS \$(0.51) Beats \$(0.56) Estimate, Sales \$49.265K Miss \$50K Estimate

Financial news for CBMG dated on 2019-03-22: 60 Biggest Movers From Yesterday

Financial news for CBMG dated on 2019-03-21: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for CBMG dated on 2019-03-21: Cellular Biomedicine shares are trading lower after the company priced a 1.03 million share common stock offering at \$17 per share.

Financial news for CBMG dated on 2019-03-21: Cellular Biomedicine Prices ~1.029M Share Offering At \$17/Share

Financial news for CBMG dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for CBMG dated on 2019-03-20: Cellular Biomedicine Group Reports Offering Of Common Stock, No Terms Disclosed

Financial news for CBMG dated on 2019-02-20: Cellular Biomedicine Gr Laet Tuesday Reported Q4 EPS \$(0.44) Beats \$(0.50) Estimate, Sales \$25.698K Miss \$50K Estimate

Financial news for CBMG dated on 2019-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2019

Financial news for CBMG dated on 2019-02-07: Baird Initiates Coverage On Cellular Biomedicine Gr with Outperform Rating, Announces \$26 Price Target

Financial news for CBMG dated on 2019-01-17: Cellular Biomedicine Group's AlloJoin Therapy For Knee Osteoarthritis Becomes The First Stem Cell Drug Application Approved In China For Phase II Clinical Trials

Financial news for CBMG dated on 2019-01-09: Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)

Financial news for CBMG dated on 2018-12-28: UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region

Financial news for CBMG dated on 2018-12-28: Cellular Biomedicine 8-K Shows Toll Manufacturing, Supply Deal With Beijing Novartis Pharma

Financial news for CBMG dated on 2018-11-08: 88 Biggest Movers From Yesterday

Financial news for CBMG dated on 2018-11-06: Cellular Biomedicine Gr Q3 EPS \$(0.56) Misses \$(0.52) Estimate, Sales \$70.431K Beat \$50K Estimate

Financial news for CBMG dated on 2018-10-12: 44 Biggest Movers From Yesterday

Financial news for CBMG dated on 2018-10-10: UPDATE: Cellular Biomedicine Group To Repurchase Shares Of Its Common Stock For A Purchase Price Not To Exceed \$8.4M

Financial news for CBMG dated on 2018-10-10: Cellular Biomedicine Group 8-K Shows On Oct. 10, Co. Commenced Buyback Program

Financial news for CBMG dated on 2018-10-04: 55 Biggest Movers From Yesterday

Financial news for CBMG dated on 2018-10-03: 43 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CBMG dated on 2018-10-03: Cellular Biomedicine Group Obtains NCI Patent License For Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology To Treat Solid Tumors

Financial news for CBMG dated on 2018-10-01: 46 Biggest Movers From Friday

Financial news for CBMG dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for CBMG dated on 2018-09-27: Cellular Biomedicine Shares To Resume Trade At 8 a.m. EDT

Financial news for CBMG dated on 2018-09-27: Cellular Biomedicine Group Reports Strategic License, Collaboration Deal With Global Leader In CAR-T Cell Therapy For

Patients In China

Financial news for CBMG dated on 2018-09-27: Cellular Biomedicine Group Shares Halted News Pending

Financial news for CBMG dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for CBMG dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for CBMG dated on 2018-08-08: Cellular Biomedicine Gr Q2 EPS \$(0.53) Down From \$(0.43) YoY, Sales \$77.313K Up From \$62.914K YoY

Financial news for CBMG dated on 2018-08-02: Stocks Which Set New 52-Week High Yesterday, August 1st

Financial news for CBMG dated on 2018-06-15: Maxim Group Terminates Cellular Biomedicine Gr Coverage

Financial news for CBMG dated on 2018-05-08: Cellular Biomedicine Reports Q1 EPS \$(0.51), Sales \$50.96M

Financial news for CBMG dated on 2018-03-16: Cellular Biomedicine Group Announces 'Positive' 48-Week Clinical Data of AlloJoin Human Adipose-Derived Mesenchymal Progenitor Cell Knee Osteoarthritis China Phase I Trial

Financial news for CBMG dated on 2018-03-05: Cellular Biomedicine Group S-3 Filing Shows Registration For ~2.93M Share Common Stock Offering Via Selling Holders

Financial news for CBMG dated on 2018-02-14: Sailing Capital Overseas Investments Fund Reports 10.1% Stake In Cellular Biomedicine

Financial news for CBMG dated on 2018-02-07: 8 Stocks Moving In Wednesday's After-Hours Session

Financial news for CBMG dated on 2018-02-05: Cellular Biomedicine Group Announces \$30.6M Investment from Sailing Capital Overseas Investment Ltd.

Financial news for CBMG dated on 2018-01-12: 46 Biggest Movers From Yesterday

Financial news for CBMG dated on 2018-01-11: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for CBMG dated on 2018-01-09: 48 Biggest Movers From Yesterday

Financial news for CBMG dated on 2018-01-08: 40 Biggest Movers From Friday

Financial news for CBMG dated on 2018-01-05: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for CBMG dated on 2017-12-28: 31 Stocks Moving In Thursday's Mid-Day Session

Financial news for CBMG dated on 2017-11-09: Cellular Biomedicine Group Reports Q3 EPS \$(0.43) vs \$(0.48) Est., Sales \$106.787M vs \$10.012M YoY

Financial news for CBMG dated on 2017-11-06: Thermo Fisher Scientific, Cellular Biomedicine Group Reports Strategic Partnership to Develop Manufacturing Processes

Financial news for CBMG dated on 2017-08-08: Cellular Biomedicine Group Reports Q2 EPS \$(0.43) vs \$(0.52) In Same Qtr. Last Year, Sales \$62.914M vs \$71.599M Est.

Financial news for CBMG dated on 2017-06-26: Cellular Biomedicine Announce Xia Meng COO

Financial news for CBMG dated on 2017-06-01: Cellular Biomedicine Reports \$10M Buyback Plan

Financial news for CBMG dated on 2017-05-15: Mid-Afternoon Market Update: Sorl Auto Parts Climbs After Strong Q1 Results; Westmoreland Shares Plunge

Financial news for CBMG dated on 2017-05-15: 18 Biggest Mid-Day Gainers For Monday

Financial news for CBMG dated on 2017-05-15: Mid-Day Market Update: Crude Oil Up 3%; Forterra Shares Drop After Q1 Results

Financial news for CBMG dated on 2017-05-15: Mid-Morning Market Update: Markets Open Higher; Thermo Fisher to Acquire Patheon For \$35/Share

Financial news for CBMG dated on 2017-05-15: Cellular Biomedicine Adds Second Clinical Site in Expansion of Chimeric Antigen Phase 1 Trial

Financial news for CBMG dated on 2017-05-15: Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma

Financial news for CBMG dated on 2017-05-08: Cellular Biomedicine Reports Q1 EPS \$(0.43) vs \$(0.35) Est., Sales \$98.425M vs \$488.491M YoY

Financial news for CBMG dated on 2017-04-10: Cellular Biomedicine Group Reports Deal with GE Healthcare Life Sciences China for Strategic Partnership to Establish Joint Technology Lab to Develop Control Processes for Manufacture of CAR-T, Stem Cell Therapies

Financial news for CBMG dated on 2017-03-14: Cellular Biomedicine FY EPS \$(2.09) vs \$(1.85) Est, Sales \$628K vs \$15M Est

Financial news for CBMG dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for CBMG dated on 2017-03-08: Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gutermann

Financial news for CBMG dated on 2017-03-03: Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market

Financial news for CBMG dated on 2017-03-03: Family Office Legend Thomas Gutermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns'

Financial news for CBMG dated on 2017-02-27: Cellular Biomedicine Group Awarded \$2.29 Million Grant from the California Institute for Regenerative Medicine

Financial news for CBMG dated on 2017-01-09: Cellular Biomedicine Gets Approval for Commencement of CALL-1 Phase 1 Trial

Financial news for CBMG dated on 2016-11-29: Cellular Biomedicine Group To Commence Phase 1 Trial For C-CAR011 In China

Financial news for CBMG dated on 2016-11-08: Cellular Biomedicine Group Reports Q3 EPS \$(0.75) vs. Prior Year Quarter \$(0.44), Rev. \$10K vs. Prior Year Quarter \$624K

Financial news for CBMG dated on 2016-09-22: Maxim Group Initiates Coverage on Cellular Biomedicine at Buy

Financial news for CBMG dated on 2016-08-09: Cellular Biomedicine Q2 EPS (\$0.52), Revenue \$71.6K, No Estimates

Financial news for CBMG dated on 2016-06-23: Dangdal International Group Reports 16.11% Stake in Cellular Biomedicine Group in 13D

Financial news for CBMG dated on 2016-06-20: Cellular Biomedicine Group Reports Secondary Offering Of Up To 5.137M Shares Of Stock

Financial news for CBMG dated on 2016-05-09: Cellular Biomedicine Reports Q1 Loss \$4.3M, Sales \$488.491K vs \$1.8M Est.

Financial news for CBMG dated on 2016-03-14: Cellular Biomedicine Group Reports FY15 EPS \$(1.70) vs. Prior Year Quarter \$(1.43)

Financial news for CBMG dated on 2016-02-04: Cellular Biomedicine's Stock Surges After Company Receives Strategic Investment

Financial news for CBMG dated on 2016-02-04: Cellular Biomedicine Group Reports \$43.13M Strategic Investment From Dangdai, 2.27M Shares At 19/Share; 10.4% Premium To Wed. Closing Price

Financial news for CBMG dated on 2016-02-04: Cellular Biomedicine Halted - News Dissemination

Financial news for CBMG dated on 2016-01-28: Cellular Biomedicine Group Names Tony Liu as CEO

Financial news for CBMG dated on 2016-01-11: Cellular Biomedicine Group Announces CEO Cap To Be Replaced By Liu

Financial news for CBMG dated on 2016-01-06: Cellular Biomedicine Reports Launch of Phase 1 Trial for AlloJoin OTS Allogeneic Stem Cell Therapy

Financial news for CBMG dated on 2015-12-22: Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin(r) Stem Cell Therapy

Financial news for CBMG dated on 2015-11-13: Cellular Biomedicine Reports Q3 EPS \$(0.44) Vs Est \$(0.43), Sales \$624.907K Vs Est \$850K

Financial news for CBMG dated on 2015-11-03: CBMG Responds to Inquiries From Investors and the Scientific Community About the Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma

Financial news for CBMG dated on 2015-10-23: Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma

Financial news for CBMG dated on 2015-10-12: Cellular Biomedicine Spikes to High on Volume

Financial news for CBMG dated on 2015-09-28: Cellular Biomedicine Group Reports Positive Results From CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients With Solid Tumors

Financial news for CBMG dated on 2015-09-28: Cellular Biomedicine Group Responds to Inquiries From Investors and the Scientific Community About Its Immuno-Oncology Cell Therapy Platform

Financial news for CBMG dated on 2015-09-16: Cellular Biomedicine Group to Present CAR-T Phase I Clinical Trial Data for Non Small Cell Lung Cancer and Other Solid Tumors at 5th World Congress on Cancer Therapy

Financial news for CBMG dated on 2015-09-14: Cellular Biomedicine Group to Release CAR-T for Non-Small Cell Lung Cancer Phase I Clinical Trial Data at 2015 European Cancer Congress

Financial news for CBMG dated on 2015-08-14: Cellular Biomedicine Group Reports Q2 Loss \$0.44 Vs Est Loss \$0.37, Sales \$656.959K Vs Est \$650.0K

Financial news for CBMG dated on 2015-08-11: Cellular Biomedicine Names Dr. Yihong Yao Chief Scientific Officer

Financial news for CBMG dated on 2015-06-09: Cellular Biomedicine Group Announces Definitive Agreement To Purchase CD40LG VAX Vaccine, Related Technologies

Financial news for CBMG dated on 2015-06-05: Cellular Biomedicine Group Reports Publication of Human Adipose-Derived Progenitor Cells to Treat Knee Osteoarthritis

Financial news for CBMG dated on 2015-05-29: Cellular Biomedicine Group to Give Business and Clinical Updates at Jefferies 2015 Global Healthcare Conference

Financial news for CBMG dated on 2015-05-27: Cellular Biomedicine Names Richard Wang as COO

Financial news for CBMG dated on 2015-05-22: Benzinga's Volume Movers

Financial news for CBMG dated on 2015-05-22: Cellular Biomedicine Group Reports Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program

Financial news for CBMG dated on 2015-05-18: Cellular Biomedicine Q1 EPS -\$0.39 vs -\$0.40 est

Financial news for CBMG dated on 2015-04-27: Cellular Biomedicine Group to Present Cancer CAR-T CD30 Therapy Clinical Development Program

Financial news for CBMG dated on 2015-04-22: Cellular Biomedicine Group Announces New Facility in Beijing

Financial news for CBMG dated on 2015-04-20: Cellular Biomedicine Group Partners With Huntsworth Health to Build Global KOL Advocacy for Knee Osteoarthritis Stem Cell ReJoin(TM) Clinical Trials

Financial news for CBMG dated on 2015-04-10: Cellular Biomedicine Group Moved to NASDAQ Global Market

Financial news for CBMG dated on 2015-04-08: Cellular Biomedicine Group Responds to False Statements, Allegations Made by Pump Stopper

Financial news for CBMG dated on 2015-04-07: Citron Research @CitronResearch Tweet: \$CBMG we warned you yesterday- report out today. Stock to \$5 pumpstopper.com/?p=345

Financial news for CBMG dated on 2015-04-07: Pump Stopper Says Cellular Biomedicine Strong Sell On Patient Death, Fraud Ties And Stock Promotion, -94.6% Downside

Financial news for CBMG dated on 2015-04-06: Citron Research @CitronResearch \$CBMG total joke of a bio stock. If you are lucky enough to get a borrow- enjoy it...stock worth \$5

Financial news for CBMG dated on 2015-03-31: Cellular Biomedicine Reports FY14 EPS (1.43) vs. Est. \$(1.53), Rev. \$564K vs. Est. \$400K

Financial news for CBMG dated on 2015-03-25: Cellular Biomedicine Group Announces Interim Results From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy

Financial news for CBMG dated on 2015-02-09: Morning Market Gainers

Financial news for CBMG dated on 2015-02-09: Cellular Biomedicine Group to Acquire Chinese PLA General Hospital's CAR-T Immuno-Oncology Technology, Clinical Data

Financial news for CBMG dated on 2015-01-06: Cellular Biomedicine Group Initiates Patient Recruitment for Cartilage Damage Stem Cell Therapy Clinical Research Study

Financial news for CBMG dated on 2014-12-23: Cellular Biomedicine Group To Exercise Stock Options to Purchase Common Stock

Financial news for CBMG dated on 2014-12-05: Cellular Biomedicine Group Releases Positive 48-Week Data From Phase I/IIa Clinical Trial For ReJoin

Financial news for CBMG dated on 2014-10-16: Cellular Biomedicine Group Launches Pre-Clinical Research Study for COPD

Financial news for CBMG dated on 2014-09-30: Cellular Biomedicine Group Completes Acquisition of Agreen Biotech Co For \$3.3M

Financial news for CBMG dated on 2014-09-10: Events for the Week of Sept. 8-12

Financial news for CBMG dated on 2014-09-10: Cellular Biomedicine Group Completes Twelve-Month Follow-Up of Patients From Phase I/IIa Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis

Financial news for CBMG dated on 2014-09-02: Morning Market Movers

Financial news for CBMG dated on 2014-09-02: Cellular Biomedicine launches Study On Human Adipose Mesenchymal Progenitor Cell

Financial news for CBMG dated on 2014-08-12: Cellular Biomedicine Says It Completed Treatment in Phase IIb Trail For Knee Osteoarthritis

Financial news for CBMG dated on 2014-08-04: Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology And U.S. Patent; \$3.28M In Cash + 753K In CBMG Stock & 75K In CBMG Restricted Units

Financial news for CBMG dated on 2014-07-07: Shares of Cellular Biomedicine Quiet Ahead of Close Amid 13G Filing from Mission Right Ltd. Showing 8.2% Stake

Financial news for CBMG dated on 2014-06-30: Cellular Biomedicine To Discontinue Consulting Business, Expects \$840,000 Pretax Charge

Financial news for CBMG dated on 2014-06-30: Cellular Biomedicine Group Discontinues Consulting Business Segment

Financial news for CBMG dated on 2014-06-26: Cellular Biomedicine Completes Phase IIB Enrollment

Financial news for CBMG dated on 2014-06-20: Cellular Biomedicine Sold 1.49M Shares at \$6.70/Share

Financial news for CBMG dated on 2014-06-19: Cellular Biomedicine Announces Positive Phase I/IIA Data Fro ReJoin

Financial news for CBMG dated on 2013-12-13: Cellular Biomedicine Group Completes Patient Treatment for Phase I Clinical Trial for Liver Cancer